Enlicitide
Investigational — oral PCSK9 peptide (enlicitide) — not approved.
Ref $ —reference only
EnlicitideIn clinical trials · Not yet FDA-approvedWhat it's for
Investigational — oral PCSK9 peptide (enlicitide) — not approved.
What it's for
Enlicitide (MK-0616) is an still being studied orally bioavailable macrocyclic peptide that inhibits PCSK9.
What it does for the body
It is studied to lower LDL cholesterol. Not approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
PCSK9 inhibition prevents LDL-receptors (lock-and-key landing spots on cells) degradation, increasing hepatic LDL clearance — same pathway class as injectable monoclonal PCSK9 inhibitors, but as an oral peptide.
Research context
Bottom line for readers: Enlicitide is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Enlicitide — FDA.gov search
- ClinicalTrials.gov search: Enlicitide — U.S. clinical trials registry
- Drugs@FDA search: Enlicitide — FDA drug database (if approved)
- PubMed search: Enlicitide — NCBI PubMed
- PubMed Central search: Enlicitide — NCBI PMC
Reference
No ref on file.